Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5][6]. Core Insights - The report emphasizes the continuous recommendation of innovative drugs and medical devices, highlighting the high growth potential in the innovative pharmaceutical sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others, indicating a potential for value re-evaluation [3][5]. - The report notes that the National Medical Insurance Administration has officially announced the 2025 medical insurance drug catalog, which includes 114 new drugs, 50 of which are first-class innovative drugs. This adjustment is seen as a validation of the support for innovation in the healthcare sector [3][5]. - The A-share pharmaceutical sector underperformed the broader market in the second week of December 2025, with the SW Pharmaceutical Biotechnology index declining by 1.0% compared to a 0.3% drop in the Shanghai Composite Index [7][18]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Medical Devices - The report highlights the sustained recommendation of innovative drugs and medical devices, with a focus on companies that are expected to see performance growth and value re-evaluation [5][6]. Section 2: A-share Pharmaceutical Sector Performance - In the second week of December 2025, the A-share pharmaceutical sector's performance was weaker than the overall market, ranking 16th among the primary industries [7][18]. Section 3: Hong Kong and US Market Performance - The report indicates that the Hong Kong pharmaceutical sector also underperformed, while the US pharmaceutical sector showed stronger performance compared to the broader market [18].

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4327.65 points, down 0.28%, with a trading volume of HKD 7.682 billion and a turnover rate of 0.9% [1] - Among the index constituents, 21 stocks rose while 36 stocks fell, with Kewei Medical leading the gainers at a 4.14% increase and Xianjian Technology leading the decliners at a 9.14% decrease [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56%, latest price at HKD 198.00, and a market cap of HKD 240.063 billion, down 0.36% [1] - Yier Eye Hospital (sz300015) with a weight of 11.62%, latest price at HKD 11.23, and a market cap of HKD 104.724 billion, down 0.62% [1] - Lejin Medical (sz300003) with a weight of 4.85%, latest price at HKD 15.64, and a market cap of HKD 28.831 billion, down 0.64% [1] - Aimeike (sz300896) with a weight of 4.80%, latest price at HKD 143.25, and a market cap of HKD 43.346 billion, up 1.47% [1] - Yuyue Medical (sz002223) with a weight of 4.66%, latest price at HKD 35.68, and a market cap of HKD 35.768 billion, up 0.17% [1] - Yingke Medical (sz300677) with a weight of 3.64%, latest price at HKD 41.76, and a market cap of HKD 27.360 billion, down 0.17% [1] - Furuijia (sz300049) with a weight of 3.59%, latest price at HKD 69.33, and a market cap of HKD 18.371 billion, down 0.82% [1] - Meinian Health (sz002044) with a weight of 3.58%, latest price at HKD 5.09, and a market cap of HKD 19.924 billion, up 0.39% [1] - Sinopharm Holdings (hk01099) with a weight of 3.35%, latest price at HKD 18.15, and a market cap of HKD 56.638 billion, down 0.40% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63%, latest price at HKD 12.23, and a market cap of HKD 26.434 billion, down 3.24% [1] Capital Flow Analysis - The index constituents experienced a net outflow of HKD 382 million from institutional investors, while retail investors saw a net inflow of HKD 329 million [1] - Notable individual stock capital flows include: - Meinian Health (sz002044) with a net inflow of HKD 23.6308 million from institutional investors [2] - Aimeike (sz300896) with a net inflow of HKD 5.8353 million from institutional investors [2] - Yier Eye Hospital (sz300015) with a net outflow of HKD 20.7620 million from retail investors [2]

Core Insights - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4406.89 points, down 0.24%, with a trading volume of HKD 7.939 billion and a turnover rate of 0.88% [1] - Among the index constituents, 23 stocks rose while 34 stocks fell, with Yiyang Sunshine leading the gainers at 3.98% and Jinxin Fertility leading the decliners at 3.89% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index are as follows: - Mindray Medical (sz300760) holds a weight of 14.56%, latest price at HKD 200.05, down 1.16%, with a market cap of HKD 242.549 billion [1] - Aier Eye Hospital (sz300015) has a weight of 11.62%, latest price at HKD 11.40, up 0.89%, with a market cap of HKD 106.31 billion [1] - Lepu Medical (sz300003) has a weight of 4.85%, latest price at HKD 15.89, up 0.38%, with a market cap of HKD 29.292 billion [1] - Aimeike (sz300896) has a weight of 4.80%, latest price at HKD 142.81, down 0.11%, with a market cap of HKD 43.213 billion [1] - Yuyue Medical (sz002223) has a weight of 4.66%, latest price at HKD 35.84, down 0.83%, with a market cap of HKD 35.929 billion [1] - Yingke Medical (sz300677) has a weight of 3.64%, latest price at HKD 43.72, up 0.97%, with a market cap of HKD 28.644 billion [1] - Furuide (sz300049) has a weight of 3.59%, latest price at HKD 70.75, up 0.71%, with a market cap of HKD 18.747 billion [1] - Meinian Onehealth (sz002044) has a weight of 3.58%, latest price at HKD 5.13, down 0.58%, with a market cap of HKD 20.08 billion [1] - Sinopharm (hk01099) has a weight of 3.35%, latest price at HKD 18.51, down 0.97%, with a market cap of HKD 57.767 billion [1] - Ping An Good Doctor (hk01833) has a weight of 2.63%, latest price at HKD 13.18, up 0.21%, with a market cap of HKD 28.495 billion [1] Capital Flow Analysis - The index constituents experienced a net outflow of main funds totaling HKD 230 million, while retail investors saw a net inflow of HKD 268 million [1] - Detailed capital flow for specific stocks shows: - Furuide (sz300049) had a main fund net inflow of HKD 8.7323 million, with retail outflows of HKD 3.3726 million [2] - Aier Eye Hospital (sz300015) had a main fund net inflow of HKD 6.6536 million, with retail outflows of HKD 1.8752 million [2] - Lepu Medical (sz300003) had a main fund net inflow of HKD 3.7716 million, with retail outflows of HKD 0.7273 million [2]

2025 年三季报总结：医疗器械、生命科学上游、疫苗 20251205 摘要 2025 年医疗器械行业整体业绩承压，但第三季度收入端同比转正，归 母净利润下滑收窄，主要受国内医保控费和海外地缘政治影响，预计 2026 年恢复正常增速。 国内市场，2024 年医院招投标节奏放缓影响收入兑现，以旧换新政策 预计 2025 年底推动设备板块增长，IVD 板块受集采调价和补税影响承 压。 海外市场，企业加强布局但前期费用较高，短期内利润承压。中美关税 对低值耗材情绪影响显著，手套行业库存消化后价格预计年底至 2026 年回暖。 2025 年前三季度医疗设备板块收入持平，利润增速略高，影像设备以 旧换新项目落地，内窥镜板块回暖明显，国产化率提升显著。 IVD 板块前三季度同比下滑，但单三季度收入好转，受益于集采落地和 DRG/DIP 2.0 发布，免疫诊断利好国产替代，生化诊断集中度提升。 高值耗材板块收入增长，骨科增速显著，心脑血管手术量恢复带动销量， 眼科渗透率低具潜力，电生理、主动脉介入领域增长良好。 疫苗板块业绩承压，收入下滑利润转亏，但单季度环比向好，关注传统 疫苗恢复及九价 HPV 疫苗等新管线品种上市，生 ...

Group 1 - The potential for national income doubling is expected to open a "golden decade" for new consumption development, with a theoretical target of nearly doubling per capita GDP by 2035, from $13,300 in 2024 to approximately $20,000 [16][17][33] - The growth of the middle-income group is crucial for driving consumption, with a target of over 800 million middle-income individuals in the next 15 years, which will significantly influence the scale and quality of domestic consumption [42][49] - The report emphasizes the importance of promoting common prosperity to activate domestic consumption potential, highlighting that increasing the income of low-income groups can effectively convert new income into consumption [20][23][49] Group 2 - The beauty and personal care sector is expected to see growth driven by new materials in the medical beauty segment, with companies like Lepu Medical focusing on innovative materials that fill market gaps [4][5][15] - The beauty industry is entering a low-growth phase, where brand group operations and market share enhancement will be critical for sustainable growth, with companies like Mao Ge Ping and Shangmei Holdings being highlighted for their potential [4][5][15] - The pet care market is experiencing both consumption upgrades and intensified competition, with a focus on high-end, health-oriented products [4][5][15] Group 3 - The service consumption sector, particularly tourism and sports, is expected to benefit from policy encouragement, with companies like Sanxia Tourism and Lansi Co. being recommended for investment [4][5][15] - The report notes that the tourism sector is poised for growth due to increased interest in flexible vacations and the aging population, which is expected to drive demand for river cruises [4][5][15] - The sports service sector is highlighted as a core growth area, with event-driven economic activities expected to boost related industries [4][5][15] Group 4 - The IP and trendy toy market is entering a new phase with a surge in supply, and companies like Pop Mart are expected to maintain their leading positions through effective IP management [4][5][15] - The report indicates that the emergence of new designers and retail platforms is likely to sustain high demand for IP products, with a focus on companies that can effectively monetize potential IP [4][5][15] Group 5 - The gold and jewelry sector is facing short-term demand pressure due to tax reforms and seasonal fluctuations, with a focus on brands that can maintain pricing power amid these changes [5][15]

每经头条（nbdtoutiao）——秒光、售罄！银行大额存单成稀缺资源，2%以上产品很难抢，有的门槛高 达1000万元！专家：存款利率或长期下行 截至发稿，乐普医疗市值为292亿元。 每经AI快讯，乐普医疗（SZ 300003，收盘价：15.83元）12月5日晚间发布公告称，公司第六届第十九 次董事会会议于2025年12月5日在北京市昌平区超前路37号公司会议室以现场及通讯相结合的方式召 开，会议审议通过了《关于不向下修正"乐普转2"转股价格》的议案。 2025年1至6月份，乐普医疗的营业收入构成为：医疗器械占比52.72%，药品占比33.16%，医疗服务及 健康管理占比14.11%。 （记者 贾运可） ...

| 证券代码：300003 | 证券简称：乐普医疗 | 公告编号：2025-109 | | --- | --- | --- | | 债券代码：123108 | 债券简称：乐普转 2 | | 乐普（北京）医疗器械股份有限公司 第六届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称：公司）第六届董事会第十 九次会议于 2025 年 12 月 5 日在北京市昌平区超前路 37 号公司会议室以现场及 通讯相结合的方式召开，会议通知于 2025 年 11 月 28 日以邮件、电话方式通知 全体董事。会议应出席董事 7 名，实际出席董事 7 名。其中，董事王其红先生 以通讯表决方式出席会议，独立董事甘亮先生因个人原因未能亲自出席，委托独 立董事王立华先生代为出席会议并行使表决权。本次会议召开符合《公司法》及 《公司章程》的相关规定。会议由董事长蒲忠杰先生主持。出席会议的董事审议 并以记名方式投票表决通过了如下决议： 审议《关于不向下修正"乐普转 2"转股价格》的议案 二〇二五年十二月五日 根据《乐普（北 ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-110 债券代码：123108 债券简称：乐普转 2 乐普（北京）医疗器械股份有限公司 关于不向下修正"乐普转 2"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 12 月 5 日，乐普（北京）医疗器械股份有限公司（以下简 称"公司"）股票已触发"乐普转 2"转股价格向下修正条款。 2、公司于 2025 年 12 月 5 日召开第六届董事会第十九次会议，审议通过了 《关于不向下修正"乐普转 2"转股价格》的议案，公司董事会决定本次不向下 修正"乐普转 2"转股价格，且自董事会审议通过次日起至"乐普转 2"存续期 结束（即 2025 年 12 月 6 日至 2026 年 3 月 29 日），如再次触发"乐普转 2"转 股价格向下修正条款，亦不提出向下修正方案。 一、可转债发行上市概况 （一）可转债发行上市基本情况 经中国证券监督管理委员会出具的《关于同意乐普（北京）医疗器械股份有 限公司向不特定对象发行可转换公司债券注册的批复》（证监许可[2021 ...

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]